Page 85 - Clinical Olfactory Working Group Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical olfactory working group consensus statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Olfactory Working Group Consensus Statement Today - Breaking & Trending Today

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease


(0)
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile in 21 heavily pre-treated and immunocompromised patients with steroid-resistant, gastrointestinal-predominant aGvHD following stem cell transplantation
Results in line with previously observed data from a larger patient population treated with MaaT013 as part of an early access program
MaaT013 expected to advance into pivotal Phase 3 program
MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease (SR-GI-aGvHD). The study met its primary endpoint of clinical efficacy, demonstrating a combined 33.3% complete response rate (CR) or very good partial response rate (VGPR) at day 28. In addition, the overall response rate (ORR) was 38.1% at da ....

Saint Antoine , France General , Kostenloser Wertpapierhandel , John Weinberg , Mohamad Mohty , Cellular Therapy Department , European Medicines Agency , Professor Of Haematology At Sorbonne University , Drug Administration , Trophic Communications , Maat Pharma , Chief Medical Officer , Sorbonne University , Saint Antoine Hospital , Orphan Drug Designation , Microbiome Ecosystem Therapies , Stephanie May , Top Line , துறவி அன்டோயின் , பிரான்ஸ் ஜநரல் , ஜான் வெயின்பெர்க் , செல்லுலார் சிகிச்சை துறை , ப்ரொஃபெஸர் ஆஃப் ஹீமாட்டாலஜி இல் சோர்போன் பல்கலைக்கழகம் , ம்யாயாட் பார்மா , தலைமை மருத்துவ அதிகாரி , சோர்போன் பல்கலைக்கழகம் ,

Conformis, Inc.: Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants


(2)
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal knee replacement implants enable expedited surgical time and reduce length of hospital stay.
BILLERICA, Mass., March 17, 2021 (GLOBE NEWSWIRE) Conformis, Inc. (NASDAQ:CFMS) announced today that an independent, retrospective review of hospital data has concluded that Conformis iTotal knee replacement technology is more cost-effective than leading traditional, off-the-shelf implants. Importantly, this study was independently performed with no sponsorship or funding from Conformis.
The new abstract was presented by authors at the Orthopaedic Research Society 2021 Annual Meeting (ORS 2021 Annual Meeting), held in February 2021:
Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant (https://www.ors.org/Transactions/67/980.pdf), Navin Fernando MD, Ann Chancellor CCRC, Paul Manner MD, Univers ....

United States , Richardg Buch , Mark Augusti , Jason Davis , Navin Fernando , Robertw Eberle , Rylie Buch , Exchange Commission , University Of Washington , Proceedings Of Orthopaedic Research Society , Orthopaedic Research Society , Department Of Orthopaedics , Conformis Inc , Mann Chancellor , Paul Manner , Knee Arthritis Professor , Sports Medicine , Zimmer Persona , Stryker Triathlon , Chief Executive Officer , Total System , Economic Value , Custom Implants , Implant Design Affect Hospital Metrics , Fast Track Protocol , Adverse Event Rates ,

Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency


Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is supporting research to determine if Cellvizio can be effective in severe acute and/or long COVID-19 patients suffering from lingering respiratory complications. Mauna Kea Technologies is offering in-kind funding to researchers evaluating what role Cellvizio may play in the care management of COVID-19 patients, by assessing lung fibrosis and microvascularization changes, and alveolar and capillary morphology damages; symptoms observed in severe acute and/or long COVID-19 patients with mild to severe respiratory infections. Interested clinical teams can submit their projects to this website: www.landing.maunakeatech.com/covid19. ....

United States , France General , Noord Holland , Robertl Gershon , Jouket Annema , Marcus Schultz , Lieuwe Bos , Thomas Grojean , Olesyav Danilevskaya , Jouke Annema , Kirstena Mooij Kalverda , Mike Piccinino , Peter Bonta , Research Clinical Center , Malanip Health Consequences , French Financial Markets Authority Autorit , Amsterdam University Medical Center , Measure Acute , Long Term Pulmonary , Kea Technologies , Chief Executive Officer , Mauna Kea , Pulmonary Endoscopy , Netherlands Trial Registry , Professor Annema , Federal Research Clinical Center ,

Anokion SA: Anokion Announces Initiation of Multiple-Ascending Dose Portion of its Phase 1 Clinical Trial with KAN-101 for the Treatment of Celiac Disease


(0)
Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, with the third SAD cohort actively dosing patients.
KAN-101, Anokion s lead antigen-specific drug product candidate, aims to re-educate immune cells to not respond to gluten antigens. The ACeD study is a randomized, double-blind, placebo-controlled Phase 1 trial that will enroll a total of up to 40 patients with celiac disease who are on a gluten free diet. The study is composed of t ....

United States , Alicia Davis , Kostenloser Wertpapierhandel , Deborah Geraghty , Strategic Communications , Preliminary Data , Single Ascending Dose Cohorts Expected Later , Celiac Disease , ஒன்றுபட்டது மாநிலங்களில் , அலிசியா டேவிஸ் , டெபோரா ஜெரடீ , மூலோபாய தகவல்தொடர்புகள் , ப்ரிலிமிநரீ தகவல்கள் , செலியாக் நோய் ,